NIASTASE 1.2 MG
EPTACOG ALFA (ACTIVATED) : 1.2 MG · DIN 02239659 · NOVO NORDISK CANADA INC
Health Canada status: CANCELLED POST MARKET
What is NIASTASE?
NIASTASE 1.2 MG contains EPTACOG ALFA (ACTIVATED) : 1.2 MG. It is listed in the Health Canada Drug Product Database under DIN 02239659, held by NOVO NORDISK CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 22-Jul-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02239659 |
|---|---|
| Brand name | NIASTASE |
| Generic / active ingredient | EPTACOG ALFA (ACTIVATED) : 1.2 MG |
| Manufacturer | NOVO NORDISK CANADA INC |
| Strength | 1.2 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | B02BD08 COAGULATION FACTOR VIIa |
| AHFS class | 20:28.16 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 22-Jul-2013 |
| Original market date | 1999-08-05 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code B02BD08 COAGULATION FACTOR VIIa. 3 of 11 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| NIASTASE RT | 1 MG | POWDER FOR SOLUTION ; KIT | NOVO NORDISK CANADA INC | MARKETED | DIN 02417103 |
| NIASTASE RT | 2 MG | POWDER FOR SOLUTION ; KIT | NOVO NORDISK CANADA INC | MARKETED | DIN 02417111 |
| NIASTASE RT | 5 MG | POWDER FOR SOLUTION ; KIT | NOVO NORDISK CANADA INC | MARKETED | DIN 02417138 |
| NIASTASE | 2.4 MG | POWDER FOR SOLUTION | NOVO NORDISK CANADA INC | CANCELLED POST MARKET | DIN 02239660 |
| NIASTASE | 4.8 MG | POWDER FOR SOLUTION | NOVO NORDISK CANADA INC | CANCELLED POST MARKET | DIN 02239661 |
| NIASTASE RT | 1 MG | KIT ; POWDER FOR SOLUTION | NOVO NORDISK CANADA INC | APPROVED | DIN 02347113 |
| NIASTASE RT | 2 MG | KIT ; POWDER FOR SOLUTION | NOVO NORDISK CANADA INC | APPROVED | DIN 02347121 |
| NIASTASE RT | 5 MG | KIT ; POWDER FOR SOLUTION | NOVO NORDISK CANADA INC | APPROVED | DIN 02347148 |
| NIASTASE RT | 8 MG | POWDER FOR SOLUTION ; KIT | NOVO NORDISK CANADA INC | APPROVED | DIN 02417146 |
| NIASTASE RT | 8 MG | KIT ; POWDER FOR SOLUTION | NOVO NORDISK CANADA INC | APPROVED | DIN 02365669 |
Who else supplies COAGULATION FACTOR VIIa worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. COAGULATION FACTOR VIIa appears in 109 registered pack listings across 5 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.